Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

28 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-21

Study Completion Date

2018-10-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Part 1 of the study will be conducted to provide additional information on the safety and tolerability of single doses of BOS172767 in healthy participants, to evaluate the pharmacokinetic (PK) profiles (including relative bioavailability) of BOS172767 following oral administration of 3 prototype formulations in healthy participants compared to an immediate release capsule formulation (reference), and also to determine the relative bioavailability of a selected BOS172767 prototype formulation in the fed and fasted states.

Part 2 of the study will be conducted to provide additional information on the safety and tolerability of escalating single doses of the selected formulation of BOS172767 in healthy participants, to evaluate the PK profile following increased single doses of the selected formulation of BOS172767 following administration in healthy participants, and also to evaluate the dose linearity of the selected prototype.

Part 3 of the study will be conducted to provide additional information on the safety, tolerability, and PK of the selected formulation of BOS172767 following multiple ascending doses (MADs) over 14 days of dosing in healthy participants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Part 1 is comprised of a single-dose, part-randomized, open-label, 6-way crossover in 12 healthy participants. Participants will be dosed on 6 separate occasions (in 6 treatment periods), and will receive a single prototype of BOS172767 in each treatment period.

Part 2 is comprised of a single ascending dose, fixed-sequence, open-label, 3-way crossover with an optional fourth dosing period in 10 healthy participants. Participants will be dosed on 4 separate occasions (in 4 treatment periods), and will receive a single prototype of BOS172767 in each treatment period.

Part 3 is a double-blind (sponsor-open), placebo-controlled, randomized MAD part in 36 healthy participants (12 per study cohort). Participants will be dosed on 3 separate occasions (in 3 treatment periods), and will receive a single prototype of BOS172767 in each treatment period.

Parts 2 and 3 are contingent upon successful completion of Part 1.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Subjects

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Pharmacokinetics Food Effect Proton Pump Inhibitors Drug Interaction Oral Prototype Formulations

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Part 1 and 2 of the study are open-label and therefore blinding is not required. Part 3 of the study is double-blind.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part 1: Regimen A

Participants will be treated with a BOS172767 200 milligram (mg) spray dried dispersion tablet (2 × 100 mg tablets) in the fasted state on Day 1.

Group Type EXPERIMENTAL

BOS172767 tablets

Intervention Type DRUG

Oral tablets

Part 1: Regimen B

Participants will be treated with a BOS172767 200 mg lipid capsule (2 × 100 mg capsules) in the fasted state on Day 1.

Group Type EXPERIMENTAL

BOS172767 liquid capsules

Intervention Type DRUG

Oral capsules

Part 1: Regimen C

Participants will be treated with a BOS172767 200 mg micronized capsule (2 × 100 mg capsules) in the fasted state on Day 1.

Group Type EXPERIMENTAL

BOS172767 micronized capsules

Intervention Type DRUG

Oral capsules

Part 1: Regimen D

Participants will be treated with a BOS172767 200 mg immediate release reference capsule formulation (2 × 100 mg capsules) in the fasted state on Day 1.

Group Type EXPERIMENTAL

BOS172767 immediate release capsules

Intervention Type DRUG

Oral capsules

Part 1: Regimen E

Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fasted state on Day 1.

Group Type EXPERIMENTAL

BOS172767 tablets

Intervention Type DRUG

Oral tablets

BOS172767 liquid capsules

Intervention Type DRUG

Oral capsules

BOS172767 micronized capsules

Intervention Type DRUG

Oral capsules

BOS172767 immediate release capsules

Intervention Type DRUG

Oral capsules

Part 1: Regimen F

Participants will be treated with a selected dose of a prototype formulation of BOS172767 in the fed state on Day 1.

Group Type EXPERIMENTAL

BOS172767 tablets

Intervention Type DRUG

Oral tablets

BOS172767 liquid capsules

Intervention Type DRUG

Oral capsules

BOS172767 micronized capsules

Intervention Type DRUG

Oral capsules

BOS172767 immediate release capsules

Intervention Type DRUG

Oral capsules

Part 2: Regimen G

Participants will be treated with 400 mg of the selected BOS172767 prototype in the fasted state on Day 1.

Group Type EXPERIMENTAL

BOS172767 tablets

Intervention Type DRUG

Oral tablets

BOS172767 liquid capsules

Intervention Type DRUG

Oral capsules

BOS172767 micronized capsules

Intervention Type DRUG

Oral capsules

BOS172767 immediate release capsules

Intervention Type DRUG

Oral capsules

Part 2: Regimen H

Participants will be treated with 600 mg of the selected BOS172767 prototype in the fasted state on Day 1.

Group Type EXPERIMENTAL

BOS172767 tablets

Intervention Type DRUG

Oral tablets

BOS172767 liquid capsules

Intervention Type DRUG

Oral capsules

BOS172767 micronized capsules

Intervention Type DRUG

Oral capsules

BOS172767 immediate release capsules

Intervention Type DRUG

Oral capsules

Part 2: Regimen I

Participants will be treated with 800 mg of the selected BOS172767 prototype in the fasted state on Day 1.

Group Type EXPERIMENTAL

BOS172767 tablets

Intervention Type DRUG

Oral tablets

BOS172767 liquid capsules

Intervention Type DRUG

Oral capsules

BOS172767 micronized capsules

Intervention Type DRUG

Oral capsules

BOS172767 immediate release capsules

Intervention Type DRUG

Oral capsules

Part 2: Regimen J

Participants will be treated with rabeprazole on Days -3 to -1, and a selected dose of the BOS172767 prototype in the fasted state on Day 1.

Group Type EXPERIMENTAL

BOS172767 tablets

Intervention Type DRUG

Oral tablets

BOS172767 liquid capsules

Intervention Type DRUG

Oral capsules

BOS172767 micronized capsules

Intervention Type DRUG

Oral capsules

BOS172767 immediate release capsules

Intervention Type DRUG

Oral capsules

Rabeprazole

Intervention Type DRUG

Oral tablets

Part 3: Regimen K

Participants will be treated with 400 mg of a BOS172767 prototype or matching placebo once daily (QD) or twice daily (BID) for 14 days (Days 1 to 14).

Group Type EXPERIMENTAL

BOS172767 tablets

Intervention Type DRUG

Oral tablets

BOS172767 liquid capsules

Intervention Type DRUG

Oral capsules

BOS172767 micronized capsules

Intervention Type DRUG

Oral capsules

BOS172767 immediate release capsules

Intervention Type DRUG

Oral capsules

BOS172767 matching placebo capsules

Intervention Type DRUG

Oral capsules

BOS172767 matching placebo tablets

Intervention Type DRUG

Oral tablets

Part 3: Regimen L

Participants will be treated with 600 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).

Group Type EXPERIMENTAL

BOS172767 tablets

Intervention Type DRUG

Oral tablets

BOS172767 liquid capsules

Intervention Type DRUG

Oral capsules

BOS172767 micronized capsules

Intervention Type DRUG

Oral capsules

BOS172767 immediate release capsules

Intervention Type DRUG

Oral capsules

BOS172767 matching placebo capsules

Intervention Type DRUG

Oral capsules

BOS172767 matching placebo tablets

Intervention Type DRUG

Oral tablets

Part 3: Regimen M

Participants will be treated with 800 mg of a BOS172767 prototype or matching placebo QD or BID for 14 days (Days 1 to 14).

Group Type EXPERIMENTAL

BOS172767 tablets

Intervention Type DRUG

Oral tablets

BOS172767 liquid capsules

Intervention Type DRUG

Oral capsules

BOS172767 micronized capsules

Intervention Type DRUG

Oral capsules

BOS172767 immediate release capsules

Intervention Type DRUG

Oral capsules

BOS172767 matching placebo capsules

Intervention Type DRUG

Oral capsules

BOS172767 matching placebo tablets

Intervention Type DRUG

Oral tablets

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BOS172767 tablets

Oral tablets

Intervention Type DRUG

BOS172767 liquid capsules

Oral capsules

Intervention Type DRUG

BOS172767 micronized capsules

Oral capsules

Intervention Type DRUG

BOS172767 immediate release capsules

Oral capsules

Intervention Type DRUG

BOS172767 matching placebo capsules

Oral capsules

Intervention Type DRUG

BOS172767 matching placebo tablets

Oral tablets

Intervention Type DRUG

Rabeprazole

Oral tablets

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy males or healthy females of non-child bearing potential
* Age 18 to 50 years of age at time of signing informed consent
* Body mass index of 18.0 to 32.0 kilograms per meters squared (kg/m\^2) at Screening, or, if outside the range, considered not clinically significant by the investigator
* Must be willing and able to communicate and participate in the whole study
* Must have a negative Quantiferon tuberculosis test at Screening
* Must provide written informed consent
* Must agree to use an adequate method of contraception

Exclusion Criteria

* Participants who have received any investigational medicinal product (IMP) in a clinical research study within the previous 3 months prior to dosing
* Participants who are study site employees, or immediate family members of a study site or sponsor employee
* Participants who have previously been enrolled (dosed) in this study
* History of any drug or alcohol abuse in the past 2 years prior to Screening
* Regular alcohol consumption in males \>21 units per week and females \>14 units per week (1 unit = ½ pint beer, 25 milliliters \[mL\] of 40% spirit or a 125 mL glass of wine)
* Current smokers and those who have smoked within the last 12 months prior to Screening. A breath carbon monoxide reading of greater than 20 parts per million at Screening or admission
* Current users of e-cigarettes and nicotine replacement products and those who have used these products within the last 12 months prior to Screening
* Females of childbearing potential
* Participants who do not have suitable veins for multiple venepunctures/cannulation as assessed by the investigator at Screening
* Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator
* Confirmed positive drugs of abuse test result
* Positive hepatitis B surface antigen, hepatitis C virus antibody or human immunodeficiency virus results
* Evidence of renal impairment at Screening, as indicated by an estimated creatinine clearance of \<70 mL/minute using the Cockcroft-Gault equation
* History of clinically significant cardiovascular, renal, hepatic, chronic respiratory or gastrointestinal disease (including gall stones and/or cholecystectomy), neurological or psychiatric disorder, as judged by the investigator
* Serious adverse reaction or serious hypersensitivity to any drug or the IMP formulation excipients
* Adverse reaction to rabeprazole, its excipients or any proton pump inhibitors (Part 2 only)
* Presence or history of clinically significant allergy requiring treatment, as judged by the investigator. Hay fever is allowed unless it is active.
* Donation or loss of greater than 400 mL of blood within the previous 3 months
* Participants who are taking, or have taken, any prescribed or over-the-counter drug (other than 4 grams per day paracetamol or hormone replacement therapy) or herbal remedies in the 14 days before IMP administration. Exceptions may apply on a case by case basis, if considered not to interfere with the objectives of the study, as agreed by the Principal Investigator and sponsor's medical monitor.
* Participants who have any ongoing fungal infections (stable toe nail onychomycosis is allowed)
* Failure to satisfy the investigator of fitness to participate for any other reason

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Quotient Sciences

Nottingham, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017-004002-18

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

QCL118174

Identifier Type: OTHER

Identifier Source: secondary_id

BOS172767-01

Identifier Type: -

Identifier Source: org_study_id